A targeted option is here when it’s time to consider a change in treatment
Is ELAHERE right for me?
Your ovarian cancer is platinum resistant
Your cancer is positive for a type of protein called FRα (FRalpha)
You have received 1 to 3 prior types of chemotherapy
After ovarian cancer becomes platinum resistant, what’s next?
- If you or your loved one has platinum-resistant ovarian cancer, this means that the cancer came back or progressed after certain types of chemotherapy called platinum-based chemotherapy, which contains a material called platinum
- When platinum-based chemotherapy no longer works, a change in treatment approach may be needed
- If your cancer is positive for FRα, you may be eligible for targeted treatment with ELAHERE
- Speak to your doctor to learn more about ELAHERE and if it may be right for you
- ELAHERE is the first targeted therapy developed and approved for FRα+ platinum-resistant ovarian cancer
Note: The term “ovarian cancer” is used throughout this website and refers to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
What is FRα and why is it important?
- About 1 in 3 women with platinum-resistant ovarian cancer will have high levels of FRα
- FRα, or folate receptor alpha, is a protein found on the surface of some types of cancer cells, including ovarian cancer. Your doctor may refer to it as a biomarker. Biomarkers can help determine if a targeted treatment is right for you
- Before you start treatment, your doctor will test a sample from your tumor to confirm that your cancer is FRα positive. Your doctor may be able to use tissue from an earlier biopsy or surgery for testing
- ELAHERE is the first treatment for people with platinum-resistant ovarian cancer that targets FRα in order to deliver medicine inside the cell
Biomarkers may be genes, proteins, or other materials in a cell that can be tested and measured to give more information about the cancer. This information can include how the tumor is growing, or how the cancer may respond to a type of treatment
How does ELAHERE target and kill cancer cells?
ELAHERE attaches to the outside of the cancer cell
After binding to FRα, ELAHERE is taken into the cell
ELAHERE releases a strong cancer-killing drug inside the cancer cell
The cancer-killing drug can also impact other nearby cells that may be cancerous
- ELAHERE is a type of treatment called an antibody-drug conjugate (ADC)
- ADCs are different from traditional chemotherapies and are designed to treat cancer in a targeted way
Call 1–833–ELAHERE for ELAHERE Support Services
Receive future updates about ELAHERE
FRα=folate receptor alpha.
You are about to leave this site
You are about to leave ELAHERE.com and enter a website operated by a third party. ImmunoGen does not control, is not responsible for, and makes no representation as to the accuracy or any other aspect of such resource or the privacy practices of such third party. Would you like to continue?
You are about to leave this site
You are about to leave ELAHERE.com and enter a website operated by a third party. ImmunoGen does not control, is not responsible for, and makes no representation as to the accuracy or any other aspect of such resource or the privacy practices of such third party. Would you like to continue?